Abbott, camdiab and ypsomed unveil new automated insulin delivery partnership for people with diabetes

The three companies will work to accelerate development of automated insulin delivery system for people living with diabetes system is being designed to include abbott's freestyle libre® 3 sensor, camdiab's camaps fx algorithm, and ypsomed's mylife™ ypsopump® partnership demonstrates the companies' collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes barcelona, spain, april 27, 2022 /prnewswire/ -- abbott (nyse: abt), camdiab and ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (aid) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. the initial focus of the partnership will be in european countries.
ABT Ratings Summary
ABT Quant Ranking